The fate of intravenously administered tetrahydrobiopterin and its implications for heterologous gene therapy of phenylketonuria

Cary Harding, Mark Neff, Krzysztof Wild, Kelly Jones, Lina Elzaouk, Beat Thöny, Sheldon Milstien

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Tetrahydrobiopterin (BH4) is a required cofactor for the enzymatic activity of phenylalanine hydroxylase (PAH) and is synthesized de novo from GTP in several tissues. Heterologous expression of PAH in tissues other than liver is a potential novel therapy for human phenylketonuria that is completely dependent upon BH4 supply in the PAH-expressing tissue. Previous experiments with liver PAH-deficient transgenic mice that expressed PAH in skeletal muscle demonstrated transient correction of hyperphenylalaninemia only with hourly parenteral BH4 administration. In this report, the fate of intravenously administered BH4 is examined. The conclusions are that (1) BH4 administered intravenously is rapidly taken up by liver and kidney, and (2) uptake of BH 4 into muscle is relatively low. The levels of BH4 achieved in skeletal muscle following IV injection are only 10% of the amount expected were BH4 freely and equally distributed across all tissues. The half-life of BH4 in muscle is approximately 30min, necessitating repeated injections to maintain muscle BH4 content sufficient to support phenylalanine hydroxylation. The efficacy of heterologous muscle-directed gene therapy for the treatment of PKU will likely be limited by the BH4 supply in PAH-expressing muscle.

Original languageEnglish (US)
Pages (from-to)52-57
Number of pages6
JournalMolecular Genetics and Metabolism
Volume81
Issue number1
DOIs
StatePublished - Jan 2004

Fingerprint

Phenylalanine Hydroxylase
Gene therapy
Phenylketonurias
Genetic Therapy
Muscle
Muscles
Liver
Tissue
Skeletal Muscle
Injections
Hydroxylation
Guanosine Triphosphate
Phenylalanine
Transgenic Mice
Half-Life
sapropterin
Kidney
Therapeutics

ASJC Scopus subject areas

  • Biochemistry
  • Genetics
  • Endocrinology, Diabetes and Metabolism

Cite this

The fate of intravenously administered tetrahydrobiopterin and its implications for heterologous gene therapy of phenylketonuria. / Harding, Cary; Neff, Mark; Wild, Krzysztof; Jones, Kelly; Elzaouk, Lina; Thöny, Beat; Milstien, Sheldon.

In: Molecular Genetics and Metabolism, Vol. 81, No. 1, 01.2004, p. 52-57.

Research output: Contribution to journalArticle

Harding, Cary ; Neff, Mark ; Wild, Krzysztof ; Jones, Kelly ; Elzaouk, Lina ; Thöny, Beat ; Milstien, Sheldon. / The fate of intravenously administered tetrahydrobiopterin and its implications for heterologous gene therapy of phenylketonuria. In: Molecular Genetics and Metabolism. 2004 ; Vol. 81, No. 1. pp. 52-57.
@article{2ac242e6b1d24642b80149058762f1d0,
title = "The fate of intravenously administered tetrahydrobiopterin and its implications for heterologous gene therapy of phenylketonuria",
abstract = "Tetrahydrobiopterin (BH4) is a required cofactor for the enzymatic activity of phenylalanine hydroxylase (PAH) and is synthesized de novo from GTP in several tissues. Heterologous expression of PAH in tissues other than liver is a potential novel therapy for human phenylketonuria that is completely dependent upon BH4 supply in the PAH-expressing tissue. Previous experiments with liver PAH-deficient transgenic mice that expressed PAH in skeletal muscle demonstrated transient correction of hyperphenylalaninemia only with hourly parenteral BH4 administration. In this report, the fate of intravenously administered BH4 is examined. The conclusions are that (1) BH4 administered intravenously is rapidly taken up by liver and kidney, and (2) uptake of BH 4 into muscle is relatively low. The levels of BH4 achieved in skeletal muscle following IV injection are only 10{\%} of the amount expected were BH4 freely and equally distributed across all tissues. The half-life of BH4 in muscle is approximately 30min, necessitating repeated injections to maintain muscle BH4 content sufficient to support phenylalanine hydroxylation. The efficacy of heterologous muscle-directed gene therapy for the treatment of PKU will likely be limited by the BH4 supply in PAH-expressing muscle.",
author = "Cary Harding and Mark Neff and Krzysztof Wild and Kelly Jones and Lina Elzaouk and Beat Th{\"o}ny and Sheldon Milstien",
year = "2004",
month = "1",
doi = "10.1016/j.ymgme.2003.10.002",
language = "English (US)",
volume = "81",
pages = "52--57",
journal = "Molecular Genetics and Metabolism",
issn = "1096-7192",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - The fate of intravenously administered tetrahydrobiopterin and its implications for heterologous gene therapy of phenylketonuria

AU - Harding, Cary

AU - Neff, Mark

AU - Wild, Krzysztof

AU - Jones, Kelly

AU - Elzaouk, Lina

AU - Thöny, Beat

AU - Milstien, Sheldon

PY - 2004/1

Y1 - 2004/1

N2 - Tetrahydrobiopterin (BH4) is a required cofactor for the enzymatic activity of phenylalanine hydroxylase (PAH) and is synthesized de novo from GTP in several tissues. Heterologous expression of PAH in tissues other than liver is a potential novel therapy for human phenylketonuria that is completely dependent upon BH4 supply in the PAH-expressing tissue. Previous experiments with liver PAH-deficient transgenic mice that expressed PAH in skeletal muscle demonstrated transient correction of hyperphenylalaninemia only with hourly parenteral BH4 administration. In this report, the fate of intravenously administered BH4 is examined. The conclusions are that (1) BH4 administered intravenously is rapidly taken up by liver and kidney, and (2) uptake of BH 4 into muscle is relatively low. The levels of BH4 achieved in skeletal muscle following IV injection are only 10% of the amount expected were BH4 freely and equally distributed across all tissues. The half-life of BH4 in muscle is approximately 30min, necessitating repeated injections to maintain muscle BH4 content sufficient to support phenylalanine hydroxylation. The efficacy of heterologous muscle-directed gene therapy for the treatment of PKU will likely be limited by the BH4 supply in PAH-expressing muscle.

AB - Tetrahydrobiopterin (BH4) is a required cofactor for the enzymatic activity of phenylalanine hydroxylase (PAH) and is synthesized de novo from GTP in several tissues. Heterologous expression of PAH in tissues other than liver is a potential novel therapy for human phenylketonuria that is completely dependent upon BH4 supply in the PAH-expressing tissue. Previous experiments with liver PAH-deficient transgenic mice that expressed PAH in skeletal muscle demonstrated transient correction of hyperphenylalaninemia only with hourly parenteral BH4 administration. In this report, the fate of intravenously administered BH4 is examined. The conclusions are that (1) BH4 administered intravenously is rapidly taken up by liver and kidney, and (2) uptake of BH 4 into muscle is relatively low. The levels of BH4 achieved in skeletal muscle following IV injection are only 10% of the amount expected were BH4 freely and equally distributed across all tissues. The half-life of BH4 in muscle is approximately 30min, necessitating repeated injections to maintain muscle BH4 content sufficient to support phenylalanine hydroxylation. The efficacy of heterologous muscle-directed gene therapy for the treatment of PKU will likely be limited by the BH4 supply in PAH-expressing muscle.

UR - http://www.scopus.com/inward/record.url?scp=0346059411&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0346059411&partnerID=8YFLogxK

U2 - 10.1016/j.ymgme.2003.10.002

DO - 10.1016/j.ymgme.2003.10.002

M3 - Article

C2 - 14728991

AN - SCOPUS:0346059411

VL - 81

SP - 52

EP - 57

JO - Molecular Genetics and Metabolism

JF - Molecular Genetics and Metabolism

SN - 1096-7192

IS - 1

ER -